About Kenson Ventures
Kenson Ventures is a venture capital firm founded in 1999. It is primarily based out of Palo Alto, United States. As of Jun 2015, Kenson Ventures has invested in 17 companies. It primarily invests in PE round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series C round of ACD Overall, Kenson Ventures portfolio has seen 1 IPO and 12 acquisitions including key companies like Genewiz, TP Therapeutics and StemCyte. A lot of funds co-invest with Kenson Ventures, with names like Summit Partners sharing a substantial percentage of its portfolio. Kenson Ventures has team of 5 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
PE, Series B & 1 more
Portfolio IPOs
Portfolio Acquisitions
Kenson Ventures' List of Top Investments
Kenson Ventures has a portfolio of 17 companies. Their most notable investments include Genewiz and TP Therapeutics.Their portfolio spans across United States and China. They have invested in Life Sciences, High Tech, Enterprise Applications and 2 other sectors, across stages such as PE, Series B and 1 more. Here is the list of top investments by Kenson Ventures:1. Genewiz
Provider of a wide range of genomic services for the life sciences industry. The company's services include DNA sequencing, gene synthesis, plasmid preparation, site-directed mutagenesis, fragment analysis, SNP discovery sequencing, GLP/cGMP regulatory services, next-generation sequencing, bioinformatics, and other molecular biology and genomic services.
Key facts about Genewiz
- Founded Year: 1999
- Location: South Plainfield (United States)
- Stage: Acquired
- Employee Count: 310 as on Mar 31, 2026
- Investors: Orbimed, Ampersand Capital and 5 Others
- Latest Funding Round: Grant (prize money), Jun 01, 2020, $*****
- Highlight: Acquired
Developer of targeted cancer therapies. The product pipeline includes TPX-0046 for advanced solid tumors, TPX-0131 for non-small cell lung cancer, TPX-4589 for mutant solid tumors, and many more.
Key facts about TP Therapeutics
- Founded Year: 2011
- Location: San Diego (United States)
- Annual Revenue: $30.8M as on Dec 31, 2021
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $64.4M
- Employee Count: 40 as on Mar 31, 2026
- Investors: Orbimed, Nextech Invest and 10 Others
- Latest Funding Round: Conventional Debt, Oct 19, 2018, $*****
- Highlight: Acquired
3. StemCyte
Cord blood banking and regenerative therapeutics company focused on saving lives. They specialize in newborn stem cell preservation, offering families the opportunity to bank cord blood for potential future medical treatments. They operate both private and public cord blood banks, contributing to a diverse inventory for transplants and research. They are dedicated to advancing regenerative medicine through clinical trials and innovative therapies using cord blood stem cells. Their services include cord blood and tissue banking, with options for client payment plans. They provide resources and education on the benefits of stem cell preservation and its potential to treat various diseases.
Key facts about StemCyte
- Founded Year: 1997
- Location: Covina (United States)
- Stage: Public
- Total Funding till date: $23.3M
- Employee Count: 179 as on Mar 31, 2026
- Investors: Montage Capital, Yet2ventures and 7 Others
- Latest Funding Round: Conventional Debt, Nov 22, 2010, $*****
- Highlight: Public
4. ACD
Developer of a transnational research platform for biomarker analysis. The company's proprietary product includes RNAscope technology that is capable of detecting and quantifying RNA biomarkers in situ at single-molecule sensitivity. The company also provides clinical-grade assay development and biomarker analysis services to speed up biomarker validation and companion diagnostic development services. The company's technology platform helps in the development of targeted therapies for cancer and other diseases. Its product portfolio includes RNAscope probes, reagent kits, hybridization systems, and software.
Key facts about ACD
- Founded Year: 2006
- Location: Newark (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $39.4M
- Employee Count: 138 as on Mar 31, 2026
- Investors: Summit Partners, Kenson Ventures and 5 Others
- Latest Funding Round: Series C, Jun 18, 2015, $*****
- Highlight: Acquired
5. Epitomics
Life science reagents: antibodies, proteins, kits, and expert scientific support. The company provides a wide range of high-quality reagents and tools for life science research, including primary antibodies, ELISA kits, cell lines, and proteins. They offer solutions for various applications such as western blotting, flow cytometry, IHC, and ELISA. The company focuses on delivering products with high specificity and validation, including recombinant and knockout-validated antibodies. They also provide scientific support to assist researchers with experimental design and troubleshooting. The business model is B2B, offering products and services to research institutions and pharmaceutical companies. They are a trusted partner in the scientific community, with products cited in numerous publications. The company offers flexible delivery options and aims to provide rapid access to cutting-edge reagents. They also provide protocols, interactive pathways, and other resources to support research efforts. The company is committed to innovation and performance in the field of life science research.
Key facts about Epitomics
- Founded Year: 2001
- Location: Burlingame (United States)
- Stage: Acquired
- Total Funding till date: $16.2M
- Investors: Kenson Ventures, Sycamore Ventures and 1 Other
- Latest Funding Round: Series C, Jan 30, 2009, $*****
- Highlight: Acquired
Kenson Ventures' Investments by Stage
Kenson Ventures has made 1 investment in PE stage with an average round size of $10M, 1 investment in Series B stage with an average round size of $3.1M and 1 investment in Series C stage with an average round size of $22M.Stage of entry | No. of Investments |
|---|---|
PE | 1 |
Series B | 1 |
Series C | 1 |
Note: We have considered here, only first round of investments
Kenson Ventures' Investments by Sector
Kenson Ventures has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications and Sustainability Tech. Notably, it has invested in 15 Enterprise (B2B) companies, 13 Tech companies, 3 Software companies and 1 company focusing on Social impact.Sector | No. of Investments |
|---|---|
Life Sciences | 3 |
High Tech | 2 |
Enterprise Applications | 1 |
Sustainability Tech | 1 |
Note: We have considered here, only first round of investments
Kenson Ventures' Investments by Geography
Kenson Ventures has made most investments in United States (3).Kenson Ventures' recent investments
Kenson Ventures has not made any investment in 2026 so far.Here are the most recent investments by Kenson Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 18, 2015 | United States | Series C | 3665 | ||
Aug 11, 2004 | United States | PE | 1814 | ||
Mar 04, 2003 | United States | Series B | 3832 |
IPOs and Publicly Listed companies in Kenson Ventures' Portfolio
1 of Kenson Ventures' portfolio company became public - StemCyte. It got listed on the Taipei Stock Exchange (TT), in Sep 2001.Here are Kenson Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 17, 2001 | - | - | 8303 |
Acquired companies in Kenson Ventures' Portfolio
12 companies from Kenson Ventures' portfolio have been acquired. The most recent acquisition was Apexigen in Aug 2023 by Pyxis Oncology for $*****.Here are Kenson Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 23, 2023 | - | - | 8361 | |
Jun 02, 2022 | - | - | 6573 | |
Sep 26, 2018 | - | - | 2610 | |
Jul 06, 2016 | Jun 18, 2015 | Series C | 6455 | |
Jul 30, 2013 | - | - | 1422 |
Team profile of Kenson Ventures
Kenson Ventures has a team of 5 members including 1 Partner and 1 Principal located in United States. Kenson Ventures' team does not sit on the board of any company as of now.Co-investors of Kenson Ventures
Over the past 23 years, 8 investors have co-invested in Kenson Ventures's portfolio companies. This includes funds and angels.
- Invested before Kenson Ventures: New Leaf Venture Partners, Morningside and 2 others have invested in rounds before Kenson Ventures. There is 1 company where New Leaf Venture Partners has invested before Kenson Ventures and 1 company where Morningside has invested before Kenson Ventures.
- Top Co-investors of Kenson Ventures: 3 investors entered a company along with Kenson Ventures. These include investors like Summit Partners (2 companies).
- Invested after Kenson Ventures: Sycamore Ventures (1 company) is the only investor which has invested in Kenson Ventures's portfolio after their investments.
Recent News related to Kenson Ventures
•
•
•
